VNDA
Vanda Pharmaceuticals Inc. NASDAQ$7.56
Mkt Cap $446.9M
52w Low $3.81
61.2% of range
52w High $9.94
50d MA $7.59
200d MA $6.10
P/E (TTM)
-1.9x
EV/EBITDA
-3.2x
P/B
1.3x
Debt/Equity
0.0x
ROE
-67.4%
P/FCF
-4.7x
RSI (14)
—
ATR (14)
—
Beta
0.71
50d MA
$7.59
200d MA
$6.10
Avg Volume
2.5M
About
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 11, 2026 | AMC | -2.18 | -0.46 | +78.9% | 7.43 | -3.8% | -17.6% | -18.0% | -16.6% | -18.8% | -17.9% | — |
| Oct 29, 2025 | AMC | -0.31 | -0.38 | -22.6% | 5.41 | -7.9% | -20.1% | -19.6% | -17.4% | -19.6% | -17.9% | — |
| Jul 31, 2025 | AMC | -0.34 | -0.46 | -35.3% | 4.26 | -0.2% | -1.6% | +0.0% | -1.2% | -0.9% | -1.4% | — |
| May 7, 2025 | AMC | -0.55 | -0.50 | +9.1% | 4.38 | +1.1% | -3.7% | -9.8% | -8.0% | -9.1% | -10.5% | — |
| Feb 13, 2025 | AMC | -0.14 | -0.08 | +42.9% | 4.70 | -2.6% | -6.0% | -5.1% | -3.2% | -4.5% | -5.7% | — |
| Nov 6, 2024 | AMC | -0.17 | -0.09 | +47.1% | 4.89 | -1.8% | +2.7% | +6.1% | +9.2% | +10.4% | +11.7% | — |
| Jul 31, 2024 | AMC | -0.21 | -0.08 | +61.9% | 5.84 | +0.3% | -3.4% | -7.5% | -9.1% | -9.1% | -11.0% | — |
| May 8, 2024 | AMC | 0.05 | -0.07 | -240.0% | 5.36 | -3.9% | -6.5% | -6.0% | -5.8% | -4.3% | +0.0% | — |
| Feb 7, 2024 | AMC | -0.09 | -0.04 | +55.6% | 3.64 | +0.3% | +11.8% | +14.3% | +19.0% | +11.5% | +16.8% | — |
| Nov 8, 2023 | AMC | 0.00 | 0.00 | +100.8% | 4.33 | -3.5% | -21.9% | -21.2% | -21.2% | -18.0% | -18.0% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.76 | $8.05 | +39.8% | +41.5% | +41.8% | +43.8% | +49.3% | +54.7% |
| Jan 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.25 | $8.30 | +0.6% | -4.6% | -1.5% | +3.5% | -11.0% | -11.2% |
| Dec 31 | B. Riley Securities | Maintains | Buy → Buy | — | $7.03 | $8.53 | +21.3% | +25.5% | +17.4% | +11.9% | +15.6% | +21.5% |
| Dec 31 | Jefferies | Maintains | Hold → Hold | — | $7.03 | $8.53 | +21.3% | +25.5% | +17.4% | +11.9% | +15.6% | +21.5% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.35 | $5.30 | -0.9% | -3.9% | -9.5% | -10.3% | -8.6% | -6.5% |
| Oct 30 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.41 | $4.98 | -7.9% | -20.1% | -19.6% | -17.4% | -19.6% | -17.9% |
| Aug 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.60 | $4.62 | +0.4% | -2.0% | +3.3% | +0.2% | +1.5% | +0.4% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.37 | $4.38 | +0.2% | +0.2% | -3.4% | -9.6% | -7.8% | -8.9% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.59 | $4.57 | -0.4% | -2.0% | -1.7% | -4.8% | -9.8% | -8.7% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.42 | $4.54 | +2.7% | +0.9% | +2.9% | +1.6% | +0.2% | -1.6% |
Recent Filings
8-K
Vanda Pharmaceuticals Inc. -- 8-K Filing
Vanda Pharmaceuticals CEO will receive $260,000 in annual restricted stock unit awards beginning in 2026, vesting one year from grant date, contingent on stockholder meeting participation.
Apr 22
8-K
First Tracks Biotherapeutics, Inc. -- 8-K Filing
First Tracks Biotherapeutics has separated from AnaptysBio through a spin-off transaction, creating an independent public company with its own governance and operational structure going forward.
Apr 20
8-K
AnaptysBio, Inc. -- 8-K Filing
AnaptysBio completed a spin-off creating First Tracks Biotherapeutics, with detailed agreements governing asset transfers, liability assumptions, and ongoing relationships between the two independent entities.
Apr 20
8-K
Unknown — 8-K Filing
This metadata-only 8-K filing suggests Vanda Pharmaceuticals likely made a routine regulatory update or disclosure amendment, presenting minimal material news that probably won't significantly impact the stock price.
Apr 2
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Vanda Pharmaceuticals disclosed information under Regulation FD, suggesting management communicated material non-public information to investors, which could indicate significant corporate developments requiring immediate market disclosure.
Mar 10
8-K
Vanda Pharmaceuticals Inc. -- 8-K Filing
Vanda Pharmaceuticals gained FDA approval for BYSANTITM (ilsaperidone), a new atypical antipsychotic for bipolar I disorder and schizophrenia, expanding its product portfolio in psychiatry.
Feb 23
8-K
Vanda Pharmaceuticals Inc. -- 8-K Filing
Vanda Pharmaceuticals disclosed 2026 executive compensation details for leadership including Mihael H., indicating the company is formalizing pay structures for its top management team going forward.
Feb 19
8-K
Vanda Pharmaceuticals Inc. -- 8-K Filing
Vanda Pharmaceuticals faces uncertainties in executing its U.S. business strategy and advancing pipeline products through clinical development and regulatory approval, which could impact investor returns if execution falls short.
Feb 11
Data updated apr 27, 2026 7:56am
· Source: massive.com